Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Hookipa Pharma Inc (NQ: HOOK ) 0.8200 +0.0260 (+3.27%) Streaming Delayed Price Updated: 9:41 AM EDT, Jun 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 92,210 Open 0.8298 Bid (Size) 0.8200 (710) Ask (Size) 0.8400 (47) Prev. Close 0.7940 Today's Range 0.8200 - 0.8390 52wk Range 0.4100 - 1.442 Shares Outstanding 21,588,756 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting May 30, 2024 From HOOKIPA Pharma Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Intraday Session May 27, 2024 Via Benzinga Performance YTD -1.20% -1.20% 1 Month -3.53% -3.53% 3 Month +28.10% +28.10% 6 Month +63.02% +63.02% 1 Year -36.43% -36.43% More News Read More 12 Health Care Stocks Moving In Friday's Intraday Session May 24, 2024 Via Benzinga HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting May 23, 2024 From HOOKIPA Pharma Inc. Via GlobeNewswire Deep Dive Into HOOKIPA Pharma Stock: Analyst Perspectives (4 Ratings) May 21, 2024 Via Benzinga Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch May 16, 2024 Via InvestorPlace HOOK Stock Earnings: HOOKIPA Pharma Beats EPS, Beats Revenue for Q1 2024 May 09, 2024 Via InvestorPlace HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights May 09, 2024 From HOOKIPA Pharma Inc. Via GlobeNewswire Breaking Down HOOKIPA Pharma: 4 Analysts Share Their Views April 26, 2024 Via Benzinga Stocks Creating Buzz Look Now: VTAK, AMST, HOOK, MULN, KAVL April 26, 2024 Via AB Newswire Topics Artificial Intelligence Exposures Artificial Intelligence HOOKIPA Pharma: Q4 Earnings Insights March 22, 2024 Via Benzinga HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab April 25, 2024 From HOOKIPA Pharma Inc. Via GlobeNewswire Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? April 24, 2024 Via Benzinga Exposures Product Safety HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers April 24, 2024 From HOOKIPA Pharma Inc. Via GlobeNewswire HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) April 16, 2024 From HOOKIPA Pharma Inc. Via GlobeNewswire Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients April 15, 2024 Via Benzinga HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration April 10, 2024 From HOOKIPA Pharma Inc. Via GlobeNewswire HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Beats Revenue for Q4 2023 March 22, 2024 Via InvestorPlace HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights March 22, 2024 From HOOKIPA Pharma Inc. Via GlobeNewswire HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference March 06, 2024 From HOOKIPA Pharma Inc. Via GlobeNewswire Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month February 13, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session February 08, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session February 01, 2024 Via Benzinga Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal January 29, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session January 29, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
